X Mariette

Summary

Country: France

Publications

  1. ncbi [Pathophysiology of Sjögren's syndrome]
    Xavier Mariette
    Service de Rhumatologie, Hopital de Bicetre, AP HP, 94275 Le Kremlin Bicetre
    Ann Med Interne (Paris) 154:157-68. 2003
  2. ncbi Emerging biological therapies in rheumatoid arthritis
    Xavier Mariette
    Rheumatology Department, INSERM EMI 109, Bicêtre Teaching Hospital, Paris Sud University, Le Kremlin Bicetre, France
    Joint Bone Spine 71:470-4. 2004
  3. ncbi The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy
    Florence Tubach
    INSERM U738, Bichat Teaching Hospital, Xavier Bichat School of Medicine, Paris 7 University, Paris, France
    Joint Bone Spine 72:456-60. 2005
  4. ncbi Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion
    Stephan Pavy
    Service de Rhumatologie A, CHU Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
    Joint Bone Spine 73:388-95. 2006
  5. ncbi Effect of response format for clinical vignettes on reporting quality of physician practice
    Thao Pham
    Department of Rheumatology, CHU Conception, 13005 Marseille, France
    BMC Health Serv Res 9:128. 2009
  6. ncbi Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort
    Jacques Eric Gottenberg
    Rhumatologie, Hopitaux Universitaires de Strasbourg, Centre de Référence National des Maladies Auto Immunes Systémique Rares, EA 3432 Physiopathologie des Arthrites, Strasbourg, France
    Arthritis Res Ther 11:R114. 2009
  7. ncbi B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome
    Marc Ittah
    Rhumatologie, , , , , , , France
    Arthritis Res Ther 8:R51. 2006
  8. ncbi No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome
    Jacques Eric Gottenberg
    Rhumatologie, INSERM E 109, Hopital Bicetre, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, Le Kremlin Bicetre, France
    Arthritis Res Ther 8:R30. 2006
  9. ncbi [Treatment of oral dryness in Sjögren's syndrome]
    X Mariette
    Service de Rhumatologie, Hopital de Bicetre, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Le Kremlin Bicetre, France
    Rev Med Interne 25:287-93. 2004
  10. ncbi Current and potential treatments for primary Sjögren's syndrome
    Xavier Mariette
    Rheumatology Department, Bicêtre Teaching Hospital, Le Kremlin Bicetre, Paris XI University, France
    Joint Bone Spine 69:363-6. 2002

Collaborators

Detail Information

Publications110 found, 100 shown here

  1. ncbi [Pathophysiology of Sjögren's syndrome]
    Xavier Mariette
    Service de Rhumatologie, Hopital de Bicetre, AP HP, 94275 Le Kremlin Bicetre
    Ann Med Interne (Paris) 154:157-68. 2003
    ..The links between these different elements are progressively falling into place. A better understanding of the pathophysiology of SS can be expected to lead to the development of much needed new therapeutic tools...
  2. ncbi Emerging biological therapies in rheumatoid arthritis
    Xavier Mariette
    Rheumatology Department, INSERM EMI 109, Bicêtre Teaching Hospital, Paris Sud University, Le Kremlin Bicetre, France
    Joint Bone Spine 71:470-4. 2004
    ..One of the challenges for the future is to identify ingenious combinations of biological therapies capable of improving the quality and duration of responses without exacerbating side effects...
  3. ncbi The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy
    Florence Tubach
    INSERM U738, Bichat Teaching Hospital, Xavier Bichat School of Medicine, Paris 7 University, Paris, France
    Joint Bone Spine 72:456-60. 2005
    ....
  4. ncbi Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion
    Stephan Pavy
    Service de Rhumatologie A, CHU Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
    Joint Bone Spine 73:388-95. 2006
    ..CONCLUSION: Recommendations about methotrexate therapy for RA were developed. These recommendations should help to improve practice uniformity and, ultimately, to improve the management of RA...
  5. ncbi Effect of response format for clinical vignettes on reporting quality of physician practice
    Thao Pham
    Department of Rheumatology, CHU Conception, 13005 Marseille, France
    BMC Health Serv Res 9:128. 2009
    ....
  6. ncbi Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort
    Jacques Eric Gottenberg
    Rhumatologie, Hopitaux Universitaires de Strasbourg, Centre de Référence National des Maladies Auto Immunes Systémique Rares, EA 3432 Physiopathologie des Arthrites, Strasbourg, France
    Arthritis Res Ther 11:R114. 2009
    ..Little is known about systemic B-cell activation in early rheumatoid arthritis (RA). We therefore evaluated the serum levels of markers of B-cell activation in patients included in the ESPOIR early arthritis cohort...
  7. ncbi B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome
    Marc Ittah
    Rhumatologie, , , , , , , France
    Arthritis Res Ther 8:R51. 2006
    ..Our results suggest that an anti-BAFF therapeutic approach could be particularly interesting in pSS...
  8. ncbi No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome
    Jacques Eric Gottenberg
    Rhumatologie, INSERM E 109, Hopital Bicetre, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, Le Kremlin Bicetre, France
    Arthritis Res Ther 8:R30. 2006
    ..01), although no correlation was observed between BAFF polymorphism and mRNA level. In conclusion, BAFF gene polymorphism is neither involved in genetic predisposition to pSS nor associated with a specific pattern of antibody production...
  9. ncbi [Treatment of oral dryness in Sjögren's syndrome]
    X Mariette
    Service de Rhumatologie, Hopital de Bicetre, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Le Kremlin Bicetre, France
    Rev Med Interne 25:287-93. 2004
    ..New control studies with old drugs such as hydroxychloroquine, or new ones such as rituximab, are mandatory...
  10. ncbi Current and potential treatments for primary Sjögren's syndrome
    Xavier Mariette
    Rheumatology Department, Bicêtre Teaching Hospital, Le Kremlin Bicetre, Paris XI University, France
    Joint Bone Spine 69:363-6. 2002
    ....
  11. ncbi The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome
    X Mariette
    Service de Rhumatologie, Hopital de Bicetre, Assistance Publique Hopitaux de Paris, Universite Paris XI, INSERM EMI 0109, 94275 Le Kremlin Bicetre, France
    Ann Rheum Dis 62:168-71. 2003
    ..Increased levels of B lymphocyte stimulator (BLyS) have been detected in serum from patients with systemic lupus erythematosus and rheumatoid arthritis...
  12. ncbi [Anti-cytokines in the treatment of inflammation]
    Xavier Mariette
    Service de rhumatologie Hôpital de Bicêtre 94275 Le Kremlin Bicêtre
    Rev Prat 53:507-11. 2003
    ..These anticytokines represent a dramatic progress in the treatment of inflammatory diseases but we have to stay very careful concerning the possible increased risk of infection or cancer...
  13. ncbi Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry
    X Mariette
    Hopital de Bicetre, Le Kremlin Bicetre, France
    Ann Rheum Dis 69:400-8. 2010
    ..To describe cases of lymphoma associated with anti-TNF therapy, identify risk factors, estimate the incidence and compare the risks for different anti-TNF agents...
  14. ncbi Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France
    Xavier Mariette
    Service de Rhumatologie, Hôpital de Bicêtre Assistance publique Hôpitaux de Paris AP HP, Le Kremlin Bicetre, France
    Blood 99:3909-15. 2002
    ..Thus, this 3-year prospective study indicated that, whereas the risk of NHL was not significantly increased in RA patients treated with MTX, the incidence of HD appeared to be higher in these patients compared to the French population...
  15. ncbi Detection of the tax gene of HTLV-I in labial salivary glands from patients with Sjögren's syndrome and other diseases of the oral cavity
    X Mariette
    Service d immunologie clinique, Hopital Saint Louis, Paris, France
    Clin Exp Rheumatol 18:341-7. 2000
    ..To confirm a possible association between Sjögren's syndrome (SS) and the tax gene of human T lymphotropic virus type I (HTLV-I)...
  16. ncbi Is Inhibitor of differentiation 3 involved in human primary Sjögren's syndrome?
    J Sellam
    Rhumatologie, INSERM U802, Hopital Bicetre, Assistance Publique des Hopitaux de Paris, Universite Paris Sud, Le Kremlin Bicetre, France
    Rheumatology (Oxford) 47:437-41. 2008
    ..The impairment of Id3 in T cells and, possibly, in salivary glandular epithelial cells (SGECs) seems to be involved. This animal model prompted us to investigate the role of Id3 in human pSS...
  17. ncbi Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry
    F Tubach
    Universite Paris 7 Denis Diderot, INSERM U738, Assistance Publique Hopitaux de Paris AP HP, Hopital Bichat, Biostatistique et Recherche Clinique, Paris, France
    Arthritis Rheum 60:1884-94. 2009
    ..Our objective was to describe cases of TB associated with anti-TNF mAb therapy, identify risk factors, and estimate the incidence...
  18. ncbi Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry
    J E Gottenberg
    Rhumatologie, Hopitaux Universitaires de Strasbourg, Centre de Référence National des Maladies Auto Immunes Systémique Rares, EA 4438 Physiopathologie des Arthrites, Strasbourg, France
    Ann Rheum Dis 71:1815-9. 2012
    ..Very limited data are available regarding the efficacy of abatacept (ABA) in real life. The aims of this study were to determine the efficacy of ABA in rheumatoid arthritis and predicting factors of efficacy in common practice...
  19. ncbi STAT4 is a confirmed genetic risk factor for Sjögren's syndrome and could be involved in type 1 interferon pathway signaling
    N Gestermann
    Rhumatologie, Institut Pour la Santé et la Recherche Médicale INSERM U802, Universite Paris Sud 11, Hopital Bicetre, Assistance Publique Hopitaux de Paris AP HP, Le Kremlin Bicetre, France
    Genes Immun 11:432-8. 2010
    ..51), MX1 (P=2 x 10(-4), r=0.63) and IFITM1 (P=8 x 10(-3), r=0.47), suggesting that STAT4 might be involved in not only type 2 IFN production but also in type 1 IFN-mediated effects...
  20. ncbi B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome
    F Lavie
    Rheumatology Department, Hopital Bicetre, Assistance Publique Hopitaux de Paris, Institut Pour Santé et Recherche Médicale INSERM U802, Universite Paris Sud 11, Le Kremlin Bicetre, France
    Scand J Immunol 67:185-92. 2008
    ..BAFF expression is also increased in blood T cells of such patients, independently of T-cell stimulation...
  21. ncbi A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis
    C Miceli-Richard
    Rhumatologie, Institut Pour la Santé et la Recherche Médicale U 802, Universite Paris Sud 11, Hopital Bicetre, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
    Ann Rheum Dis 67:478-84. 2008
    ..To determine whether tumour necrosis factor (TNF) gene polymorphisms and/or the shared epitope are genetic predictors of the response to adalimumab (ADA) in rheumatoid arthritis (RA)...
  22. ncbi Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment
    B Denis
    Universite Paris V, Hopital Necker Enfants Malades, Service des Maladies Infectieuses et Tropicales, Centre d Infectiologie Necker Pasteur, Paris, France
    Clin Microbiol Infect 14:183-6. 2008
    ..These data support the concept that TNF-alpha antagonists can be restarted in TB patients provided that adequate anti-TB treatment has been completed...
  23. ncbi Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome
    J E Gottenberg
    Rhumatologie, Universite Paris Sud 11, INSERM U802, Hopital Bicetre, Assistance Publique des Hopitaux de Paris, Le Kremlin Bicetre, France
    Ann Rheum Dis 66:23-7. 2007
    ..B cell activation may result in an increased secretion of immunoglobulin free light chains (FLCs) in autoimmune diseases...
  24. ncbi Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome
    J-E Gottenberg
    Service de Rhumatologie, , , , France
    Ann Rheum Dis 64:1050-5. 2005
    ..CONCLUSIONS: Serum beta2 microglobulin and BLyS reflect B cell activation in different ways in pSS. Serum beta2 microglobulin assessment could be helpful as an activity marker in pSS...
  25. ncbi Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry
    A Mekinian
    Department of Internal Medicine, Hopital Jean Verdier, Assistance Publique Hopitaux de Paris, Université Paris Sud 13, Bondy, France
    Ann Rheum Dis 71:84-7. 2012
    ..To evaluate rituximab (RTX) in primary Sjögren's syndrome (pSS) with peripheral nervous system (PNS) involvement...
  26. ncbi Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry
    X Puechal
    Le Mans General Hospital, Le Mans, and Cochin Hospital, Paris, France
    Arthritis Care Res (Hoboken) 64:331-9. 2012
    ..We assessed the efficacy and safety of rituximab in a real-life clinical setting among patients with systemic rheumatoid vasculitis (SRV)...
  27. ncbi Anti-p53 antibodies are rarely detected in serum of patients with rheumatoid arthritis and Sjögren's syndrome
    X Mariette
    Service d immuno hématologie, Laboratoire d Immunologie, Hopital Saint Louis, UMR 218 du CNRS, Institut Curie, Paris, France
    J Rheumatol 26:1672-5. 1999
    ..To detect evidence of abnormalities of the p53 protein in autoimmune diseases. Mutation of the p53 protein may inhibit apoptosis and thereby lead to cancer and possibly play a role in the pathogenesis of autoimmune diseases...
  28. ncbi Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
    J-E Gottenberg
    Service de Rhumatologie, , , , France
    Ann Rheum Dis 64:913-20. 2005
    ..This study showed good tolerance and short term clinical efficacy, with marked corticosteroid reduction in patients with SLE, pSS, vasculitis, and polymyositis...
  29. ncbi Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry
    D Salmon-Ceron
    Service de Rhumatologie, Hopital Bicetre, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre
    Ann Rheum Dis 70:616-23. 2011
    ..Anti-tumour necrosis factor (TNF) therapy may be associated with opportunistic infections (OIs)...
  30. ncbi Quantitative assessment of antibodies to ribonucleoproteins in primary Sjögren syndrome: correlation with B-cell biomarkers and disease activity
    S Candon
    INSERM U580, Hopital Necker Enfants Malades, Paris, France
    Ann Rheum Dis 68:1208-12. 2009
    ..To assess the added value of using a radioligand assay (RLA) compared with ELISA to detect antibodies to SSA, SSB and RNP, and to analyse the correlation between autoantibody levels, B-cell biomarkers and disease activity...
  31. ncbi Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry
    B Terrier
    Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie Paris 6, Paris, France
    Arthritis Care Res (Hoboken) 62:1787-95. 2010
    ..Rituximab has emerged as a novel and promising therapeutic alternative, but data are scarce. Our objective was to evaluate the safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis in off-trial real-life patients...
  32. ncbi Azathioprine or methotrexate maintenance for ANCA-associated vasculitis
    Christian Pagnoux
    Universite Paris Descartes, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    N Engl J Med 359:2790-803. 2008
    ..However, azathioprine and methotrexate have not been compared with regard to safety and efficacy...
  33. ncbi French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers
    X Mariette
    Service de Rhumatologie, , , , Paris, , , Paris, France. Recherche sur Anti-TNF et Infections Opportunistes
    Ann Rheum Dis 62:791. 2003
  34. ncbi Lymphomas in patients with Sjögren's syndrome: review of the literature and physiopathologic hypothesis
    X Mariette
    Service d Immuno Hématologie Hôpital Saint Louis, Paris, France
    Leuk Lymphoma 33:93-9. 1999
    ..If this hypothesis was correct, most of B-cell lymphomas associated with SS should have a surface immunoglobulin with RF activity and should grow through an auto-antigen driven process...
  35. ncbi Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome
    J-E Gottenberg
    Department of Rheumatology, , INSERM EMI 109, , France
    Ann Rheum Dis 64:114-7. 2005
    ..Anti-CCP positive patients, who may be prone to developing rheumatoid arthritis, require cautious clinical and radiographic follow up...
  36. ncbi Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database
    Christian Pagnoux
    Universite Paris Descartes, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Arthritis Rheum 62:616-26. 2010
    ..This study was undertaken to describe the main characteristics of and long-term outcomes in patients with well-characterized PAN diagnoses...
  37. ncbi Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases
    B Fautrel
    Department of Rheumatology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Ann Rheum Dis 64:262-6. 2005
    ..Consensus is lacking on treatment for corticosteroid resistant adult onset Still's disease (ASD)...
  38. ncbi Treatment of multiple myeloma
    Didier Clerc
    Rheumatology Department, Hopital de Bicetre, Le Kremlin Bicetre, France
    Joint Bone Spine 70:175-86. 2003
    ..After reviewing the rationale, effectiveness, and safety of each of these treatments, we will discuss the indications that we believe are legitimate...
  39. ncbi Mucosa-associated lymphoid tissue lymphoma of the thymus: a case report with no evidence of MALT1 rearrangement
    Nicolas Ortonne
    Departement de Pathologie, Hopital Henri Mondor, AP HP, avenue du Maréchal de Lattre de Tassigny 51, 94010, Creteil, France
    Virchows Arch 446:189-93. 2005
    ..They also suggest the absence of a relationship between TML and PMBL...
  40. ncbi Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
    Michel De Bandt
    Rheumatology Department, Hopital Robert Ballanger, Aulnay sous Bois, France
    Arthritis Res Ther 7:R545-51. 2005
    ..19% with infliximab and 7/3800 = 0.18% with etanercept. Clinicians should be aware that lupus syndromes with systemic manifestations may occur in patients under anti-TNF alpha treatment...
  41. ncbi Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists
    F Tubach
    Universite Paris 7, Faculte de Medecine, Paris, France
    Clin Infect Dis 43:e95-100. 2006
    ..Patients treated with tumor necrosis factor-alpha (TNF-alpha) antagonists have an increased risk of infection, but infection due to Legionella pneumophila has rarely been described in patients receiving such therapy...
  42. ncbi Lymphomas complicating Sjögren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells
    X Mariette
    Department of Rheumatology, Hopital de Bicetre, Universite Paris Sud, Le Kremlin Bicetre, France
    Ann Rheum Dis 60:1007-10. 2001
    ....
  43. ncbi Nucleotidic sequence analysis of the variable domains of four human monoclonal IgM with an antibody activity to myelin-associated glycoprotein
    X Mariette
    Laboratory of Immunopathology, Hopital Saint Louis, Paris, France
    Eur J Immunol 23:846-51. 1993
    ....
  44. ncbi Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies
    Corinne Miceli-Richard
    Rhumatologie, Hopital Bicetre, Assistance Publique Hopitaux de Paris, 94275 Le Kremlin Bicetre, France
    Arthritis Res Ther 11:R77. 2009
    ..We investigated the EBV load and EBV-specific T-cell response in patients treated with methotrexate (MTX) or anti-TNF therapy...
  45. ncbi Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis
    Bruno Fautrel
    Service de Rhumatologie, Groupe Hospitalier Pitie Salpetriere, UFR de Medecine, Universite Pierre et Marie Curie Paris VI, 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Joint Bone Spine 73:433-41. 2006
    ..To develop recommendations for TNFalpha-antagonist therapy in patients with rheumatoid arthritis (RA) seen in everyday practice, under the aegis of the French Society for Rheumatology...
  46. ncbi Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update
    Thao Pham
    Rheumatology Department, La Conception Teaching Hospital, 147 Boulevard Baille, 13005 Marseille, France
    Joint Bone Spine 74:638-46. 2007
    ..To update French Society for Rheumatology guidelines regarding the use of tumor necrosis factor alpha (TNFalpha) antagonists for treating patients with ankylosing spondylitis (AS) or psoriatic arthritis (PsA)...
  47. ncbi Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie
    V Leblond
    Departement d Hematologie, Hopital Pitie Salpetriere, Paris, France
    J Clin Oncol 16:2060-4. 1998
    ..We report our experience on the activity and toxicity of fludarabine in 71 patients with WM resistant to prior chemotherapy regimens...
  48. ncbi Vaccination in adults with auto-immune disease and/or drug related immune deficiency: results of the GEVACCIM Delphi survey
    P Duchet-Niedziolka
    Universite Paris Descartes, Faculté de Médecine AP HP, Groupe Hospitalier Cochin Saint Vincent De Paul, Pôle de médecine, CIC de Vaccinologie Cochin Pasteur INSERM, CIC BT505, Paris, France
    Vaccine 27:1523-9. 2009
    ..The objective of this study was to obtain professional agreement on vaccine practices in these patients...
  49. ncbi No evidence for association between 1858 C/T single-nucleotide polymorphism of PTPN22 gene and primary Sjögren's syndrome
    M Ittah
    Service de Rhumatologie, Institut Pour la Santé et la Recherche Médicale E 109, Hopital de Bicetre, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
    Genes Immun 6:457-8. 2005
    ..PTPN 22 gene polymorphism was not associated with a specific pattern of autoantibody secretion either. Thus, 1858 C/T polymorphism of PTPN22 gene is not involved in genetic predisposition to pSS...
  50. ncbi Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production
    Frédéric Lavie
    Rheumatology Department, Hopital Bicetre, Assistance Publique Hopitaux de Paris, Institut Pour la Santé et la Recherche Médicale INSERM U802, Universite Paris Sud 11, Le Kremlin Bicetre, France
    Ann Rheum Dis 66:700-3. 2007
    ..The cytokine B cell-activating factor of the TNF family (BAFF) is involved in the pathogenesis of autoimmune diseases...
  51. ncbi Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome
    Raphaele Seror
    Department of Rheumatology, Hopital Bicetre, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, INSERM U802, Le Kremlin Bicetre, France
    Ann Rheum Dis 66:351-7. 2007
    ..To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers...
  52. ncbi EBV-specific T-cell response and immunosuppression by methotrexate and TNFalpha antagonists in patients with chronic inflammatory joint disease
    Corinne Miceli-Richard
    Service de Rhumatologie, , , , France
    Joint Bone Spine 74:560-2. 2007
  53. ncbi Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy
    Jacques-Eric Gottenberg
    , Paris, France
    Arthritis Rheum 48:2019-24. 2003
    ....
  54. ncbi Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment
    Maxime Breban
    Hopital Ambroise Pare, Assistance Publique Hopitaux de Paris, Boulogne Billancourt, France
    Arthritis Rheum 58:88-97. 2008
    ..This study was undertaken to compare the efficacy of continuous treatment with infliximab with that of a treatment regimen adapted to symptom recurrence. Methotrexate (MTX) in combination with infliximab was also tested...
  55. ncbi Rituximab: a new therapeutic alternative in rheumatoid arthritis
    Jean Sibilia
    Service de Rhumatologie, CHU Strasbourg, Centre National de Référence des Maladies Auto immunes Systémiques Rares, Strasbourg, France
    Joint Bone Spine 75:526-32. 2008
    ..A longer follow-up duration and data from off-trial patients, included in registries, are now required...
  56. ncbi Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis
    Stephan Pavy
    Service de Rhumatologie, Hopital Bicetre, 78 Avenue du General LeClerc, 94275 Le Kremlin Bicetre, France
    Ann Rheum Dis 69:1022-8. 2010
    ..Several studies have suggested that the rare A allele of the tumour necrosis factor alpha (TNFA) -308G-->A polymorphism could be associated with a poorer response to anti-TNF therapy. Nevertheless, these results remain controversial...
  57. ncbi [Gougerot-Sjögren syndrome. Risk of lymphoma]
    X Mariette
    Service d immunologie clinique, Hopital Saint Louis, Paris
    Presse Med 28:1214-8. 1999
    ..These B lymphocytes would then proliferate secondarily...
  58. ncbi A new defensive mechanism to prevent apoptosis in salivary ductal cells from patients with Sjögren's syndrome: over-expression of p53 and p21
    X Mariette
    Service de Rhumatologie, , , , , France
    Rheumatology (Oxford) 41:96-9. 2002
    ..The lack of over-expression of p53 and p21 in acinar cells could be one of the key mechanisms of acinus destruction by apoptosis in SS and could be a target for new therapeutic strategies...
  59. ncbi [Polyclonal B lymphocytosis and hyper-IgM: immunodeficiency and/or benign lymphoid proliferation associated with tobacco?]
    S Vignes
    Service d immunohématologie, Hopital Saint Louis, Paris, France
    Rev Med Interne 21:236-41. 2000
    ....
  60. ncbi Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma
    X Mariette
    Service d immuno hématologie, Hopital Saint Louis, Paris, France
    Br J Haematol 104:723-9. 1999
    ..4, 95% CI 4.3-213) and bone marrow plasmacytosis >20% (P=0.004, HR 16.4, 95% Cl 2.6-104). Thus, spinal MRI but not bone densitometry, appeared to be justified in patients with stage I asymptomatic MM and negative skeletal survey...
  61. ncbi Tocilizumab: therapy and safety management
    Thao Pham
    Service de Rhumatologie, CHU Conception, Marseille, France
    Joint Bone Spine 77:S3-100. 2010
    ..To develop fact sheets about tocilizumab, in order to assist physicians in the management of patients with inflammatory joint disease...
  62. ncbi Abatacept therapy and safety management
    Thao Pham
    Service de Rhumatologie, CHU Conception, Marseille, France
    Joint Bone Spine 76:S3-S55. 2009
    ..To elaborate a how-to-use abatacept material intended to help physicians in the management of patients with inflammatory diseases treated with this drug in routine practice...
  63. ncbi Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature
    Jean Marie Berthelot
    Service de Rhumatologie, Hotel Dieu, CHU Nantes, 44093, Nantes Cedex 01, France
    Joint Bone Spine 76:28-34. 2009
    ..To report on the outcome of 15 cases of pregnancies in women treated with anti-TNF drugs during conception or pregnancy..
  64. ncbi B-cell-activating factor expressions in salivary epithelial cells after dsRNA virus infection depends on RNA-activated protein kinase activation
    Marc Ittah
    Rhumatologie, Institut Pour la Santé et la Recherche Médicale, Hopital Bicetre, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, Le Kremlin Bicetre, France
    Eur J Immunol 39:1271-9. 2009
    ..Thus, PKR is the dsRNA sensor implicated in BAFF induction in SGEC after dsRNA stimulation. In autoimmune diseases, PKR may be an interesting target for preventing BAFF following the induction of innate immunity...
  65. ncbi Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein-Barr virus
    Fanny Baran-Marszak
    INSERM E109, CHU Bicetre, Assistance Publique Hopitaux de Paris, Université Paris 11, 94275 Le Kremlin Bicetre, France
    Cytokine 33:337-45. 2006
    ..Thus, if an increased incidence of lymphoma were induced by TNFalpha blockers, it would not involve a direct effect on B cells but rather an impaired immune surveillance by T cells...
  66. ncbi Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion
    Thao Pham
    Service de Rhumatologie, CHU de la Conception, Marseille, France
    Joint Bone Spine 73:379-87. 2006
    ....
  67. ncbi Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome
    Frédéric Lavie
    Service de Rhumatologie, Hopital de Bicetre, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
    J Pathol 202:496-502. 2004
    ..In conclusion, BAFF may be expressed by T cells at the site of autoimmune damage and could play a role in the pathogenesis of pSS, particularly by triggering the activation of self-antigen-driven autoimmune B cells...
  68. ncbi TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology
    Thao Pham
    Service de Rhumatologie, CHU de la Conception, 147, Bd Baille, 13005 Marseille, France
    Joint Bone Spine 73:547-53. 2006
    ..To develop recommendations for TNFalpha antagonist therapy in patients with spondyloarthropathies...
  69. ncbi Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS)
    Xavier Mariette
    Service de Rhumatologie, Hôpital de Bicêtre AP HP, and Université Paris Sud, Le Kremlin Bicetre, France
    Arthritis Rheum 50:1270-6. 2004
    ..Since tumor necrosis factor alpha (TNF alpha) could be a key element in the pathogenesis of primary SS, we conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of infliximab in primary SS...
  70. ncbi Sjogren's syndrome is associated with and not secondary to systemic sclerosis
    Carine Salliot
    Rheumatology Department, Paris Sud 11 University, INSERM U802, France
    Rheumatology (Oxford) 46:321-6. 2007
    ..We aimed to determine whether SS, accompanying systemic sclerosis (SSc), could be considered secondary to or associated with SSc and whether the coexistence of both modifies the severity and the outcome of each disease. Patients and..
  71. ncbi Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?
    David Saadoun
    Department of Hematology, Hopital Necker, Paris, France
    Blood 105:74-6. 2005
    ..This study underscores the role of HCV in the lymphomagenesis and the benefit of antiviral treatment for patients presenting with HCV-driven lymphoproliferations...
  72. ncbi Quality of life and psychological status in patients with primary Sjögren's syndrome and sicca symptoms without autoimmune features
    Julien Champey
    , , , , France
    Arthritis Rheum 55:451-7. 2006
    ..The strong correlation between the composite physical and mental scores of the SF-36 and the GSI scores of the SCL-90-R in primary SS patients emphasizes the importance of the psychological dimension in results of the SF-36...
  73. ncbi High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe
    Jean Paul Fermand
    Immuno Hematology Unit and Department of Biostatistics, Hopital Saint Louis, Paris, France
    J Clin Oncol 23:9227-33. 2005
    ..To study the impact of high-dose therapy (HDT) with autologous stem-cell support in patients with symptomatic multiple myeloma (MM) between the ages of 55 and 65 years...
  74. ncbi Therapeutic potential for B-cell modulation in Sjögren's syndrome
    Xavier Mariette
    Hopital Bicetre, Assistance Publique Hopitaux de Paris AP HP, Universite Paris Sud 11, Le Kremlin Bicetre, Institut Pour la Santé et la Recherche Médicale INSERM U 802, France
    Rheum Dis Clin North Am 34:1025-33, x. 2008
    ..This B-cell activation is firstly polyclonal but can progress to monoclonal B-cell lymphoproliferation. This article addresses the therapeutic potential of B-cell modulation in Sjögren's syndrome...
  75. ncbi Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion
    Laure Gossec
    Rheumatology Department, Cochin Teaching Hospital, Paris, France
    Joint Bone Spine 72:229-34. 2005
    ..They should help to improve practice uniformity and, ultimately, to improve the management of RA...
  76. ncbi Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
    Jacques Tebib
    Service de Rhumatologie, Centre Hospitalier Lyon Sud, 765 chemin du Grand Revoyet, 69495 Pierre Benite, France
    Arthritis Res Ther 11:R95. 2009
    ..This study evaluates the safety and efficacy of masitinib (AB1010), a potent and selective protein tyrosine kinase inhibitor of c-KIT, in the monotherapy treatment of DMARD-refractory RA...
  77. ncbi Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion
    Thao Pham
    Service de Rhumatologie, CHU de la Conception, Marseille, France
    Joint Bone Spine 72:222-8. 2005
    ..Because they constitute an objective foundation built by consensus among experts, should improve the uniformity and quality of care provided to RA patients in everyday practice...
  78. ncbi Role and modalities of information and education in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion
    Bruno Fautrel
    Service de Rhumatologie, , Paris, France
    Joint Bone Spine 72:163-70. 2005
    ..7% to 100%. CONCLUSION: Recommendations about educating and informing patients with RA in everyday practice were developed. They should increase practice uniformity and ultimately optimize the management of patients with RA...
  79. ncbi Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity
    Jeremie Sellam
    Rhumatologie, Hopital Bicetre, Assistance Publique Hopitaux de Paris AP HP, INSERM U802, Universite Paris Sud 11, 78 rue du General Leclerc, 94270, Le Kremlin Bicetre, France
    Arthritis Res Ther 11:R156. 2009
    ....
  80. ncbi Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry
    Benjamin Terrier
    Bicetre Hospital, Assistance Publique Hopitaux de Paris, and Paris 11 University, Le Kremlin Bicetre, France
    Arthritis Rheum 62:2458-66. 2010
    ..However, in 2 recent randomized controlled trials (RCTs) of RTX, the primary end points were not met. We undertook this study to evaluate the safety and efficacy of RTX in off-trial patients with SLE seen in regular clinical practice...
  81. ncbi Association of transforming growth factor beta1 and tumor necrosis factor alpha polymorphisms with anti-SSB/La antibody secretion in patients with primary Sjögren's syndrome
    Jacques Eric Gottenberg
    Hopital de Bicetre, Assistance Publique Hopitaux de Paris, INSERM EMI 109, Le Kremlin Bicetre, France
    Arthritis Rheum 50:570-80. 2004
    ....
  82. ncbi Pathogenesis of Sjögren's syndrome and therapeutic consequences
    Xavier Mariette
    Hopital Bicetre, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, Institut Pour la Santé et la Recherche Médicale U1012, Le Kremlin Bicetre, France
    Curr Opin Rheumatol 22:471-7. 2010
    ....
  83. ncbi Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection
    Olivier Hermine
    Department of Hematology and Centre National de la Recherche Scientifique Unité Mixte de Recherche 8603, Hopital Necker, Paris, France
    N Engl J Med 347:89-94. 2002
    ..We undertook this study after a patient with splenic lymphoma with villous lymphocytes had a hematologic response after antiviral treatment of HCV infection...
  84. ncbi RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma
    Sophie Roux
    Service de Rhumatologie, Hopital de Bicetre, France
    Br J Haematol 117:86-92. 2002
    ..These results suggest that RANKL overexpressed by bone marrow stromal cells may contribute to the high rate of bone resorption observed in MM...
  85. ncbi Failure to confirm coxsackievirus infection in primary Sjögren's syndrome
    Jacques-Eric Gottenberg
    , , , France
    Arthritis Rheum 54:2026-8. 2006
  86. ncbi Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery
    Benjamin Terrier
    Department of Hematology, Hopital Necker Enfants Malades, Assistance Publique Hopitaux de Paris, université Paris V René Descartes, Paris, France
    Haematologica 92:e20-3. 2007
    ..Assessment of serum BAFF levels following rituximab could detect patients at risk of developing LON...
  87. ncbi Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy
    Jeremie Sellam
    Service de Rhumatologie, Hopital de Bicetre, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Ann Rheum Dis 66:1610-5. 2007
    ..We aimed to investigate in vitro blood assays with TB-specific antigens (CFP-10, ESAT-6), in immune-mediated inflammatory diseases (IMID) for LTBI screening...
  88. ncbi Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis
    Jeremie Sellam
    Service de Medecine Interne, Centre Hospitalier Universitaire Pitie Salpetriere, Universite Paris VI Pierre et Marie Curie, Centre de Reference National Pour les Lupus et le Syndrome des Antiphospholipides, Paris, France
    Joint Bone Spine 74:446-52. 2007
    ....
  89. ncbi Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion
    Emmanuelle Dernis
    Service de Rhumatologie, CH Le Mans, Le Mans, France
    Joint Bone Spine 74:330-7. 2007
    ..To develop French recommendations about the clinical and laboratory follow-up of patients with axial ankylosing spondylitis (AS) seen in everyday practice...
  90. ncbi Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion
    Frédéric Lavie
    Service de Rhumatologie, Hopital de Bicetre, Le Kremlin Bicetre, France
    Joint Bone Spine 74:346-52. 2007
    ..To develop recommendations about pharmacotherapy (excluding biotherapeutic agents) in patients with axial forms of ankylosing spondylitis (AS) seen in everyday clinical practice...
  91. ncbi Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus
    Jeremie Sellam
    Service de Rhumatologie, Hopital de Bicetre, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Ann Rheum Dis 66:790-7. 2007
    ..To analyse B cell activating factor (BAFF) receptor (BAFF-R) expression on peripheral lymphocytes from patients with primary Sjögren's syndrome (pSS) and systemic lupus erythematosus (SLE)...
  92. ncbi Imaging for the diagnosis and follow-up of ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion
    Stephan Pavy
    service de médecine interne 1, CHU Pitie Salpetriere, Paris, France
    Joint Bone Spine 74:338-45. 2007
    ..To develop recommendations regarding imaging studies for the diagnosis and follow-up of patients with axial forms of ankylosing spondylitis (AS) seen in everyday practice...
  93. ncbi Anticentromere antibodies identify patients with Sjögren's syndrome and autoimmune overlap syndrome
    Carine Salliot
    Assistance Publique Hopitaux de Paris AP HP, Hopital Bicetre, Service de Rhumatologie, Universite Paris Sud 11, 78 Rue de Général Leclerc, Le Kremlin Bicetre, France
    J Rheumatol 34:2253-8. 2007
    ..To assess the prevalence and clinical and immunological significance of anticentromere antibodies (ACA) in patients with primary Sjögren's syndrome (pSS)...
  94. ncbi Perioperative management of patients with rheumatoid arthritis treated with TNF-alpha blocking agents
    Philippe Goupille
    Semin Arthritis Rheum 37:202-3; author reply 203. 2007
  95. ncbi Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities
    Christelle Vauloup
    Service de Microbiologie-Immunologie Biologique, ,
    Eur Cytokine Netw 17:290-3. 2006
    ..In contrast, TNF antagonists may favour emergence of cryoglobulinaemia in such patients...
  96. ncbi Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance
    Eric Toussirot
    J Rheumatol 33:1027-8. 2006
  97. ncbi Methotrexate treatment and mortality in rheumatoid arthritis
    Jean Sibilia
    Lancet 360:1096-7. 2002
  98. ncbi Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis
    Bruno Fautrel
    Pierre and Marie Curie University Paris VI, UFR de Medecine, France
    Joint Bone Spine 74:627-37. 2007
    ..To update French Society for Rheumatology guidelines regarding the use of TNFalpha antagonists for treating patients with rheumatoid arthritis (RA)...
  99. ncbi The B cell: a new therapeutic target in rheumatoid arthritis and other autoimmune diseases
    Xavier Mariette
    Joint Bone Spine 71:357-60. 2004
  100. ncbi Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists
    Haifa Hamdi
    INSERM UMR S764, Service d Hepato gastro enterologie, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Institut Paris Sud sur les Cytokines, Universite Paris Sud, INSERM U764, 32 rue des Carnets, 92140, Clamart, France
    Arthritis Res Ther 8:R114. 2006
    ..Such a dual effect may explain the increased incidence of TB in patients treated with TNF antagonists as well as possible differences between TNF antagonists for the incidence and the clinical presentation of TB reactivation...
  101. ncbi Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
    Gerd R Burmester
    Department of Rheumatology and Clinical Immunology, Charite University Medicine Berlin, Chariteplatz 1, 10117 Berlin, Germany
    Ann Rheum Dis 66:732-9. 2007
    ..To evaluate the safety and effectiveness of adalimumab alone or in combination with standard disease-modifying antirheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA)...